相关实验视频

Updated: Jan 18, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

多种药物不耐症综合征和动脉高血压-系统性审查和元分析

Jakub Rusinek¹, Kinga Tyjas², Wiktoria Ziółek³

¹Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-538 Krakow, Poland.

Journal of clinical medicine

|September 13, 2025

概括

多种药物不耐症综合征 (MDIS) 影响10%的高血压患者,导致血压失控. 女性性别,年龄较大和心理健康状况是MDIS的关键风险因素. 需要进一步的研究.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
公共卫生公共卫生

背景情况:

动脉高血压 (HT) 是一种广泛的疾病,与严重的发病率和死亡率有关.
多种药物不耐症综合征 (MDIS),其特点是对三种或更多类药物不耐受,使HT的管理复杂化.
了解MDIS的流行和影响对于改善患者的治疗结果至关重要.

研究的目的:

系统地审查和元分析高血压患者中MDIS的患病率.
调查MDIS对高血压控制的影响,并确定相关的风险因素.

主要方法:

在2024年6月进行了主要数据库 (MEDLINE,Scopus,Web of Science,Embase) 的全面搜索.
数据提取包括MDIS患病率,危险因素,药物不良反应 (ADRs) 和反应类型.
经过元分析,根据PRISMA指南,确定了聚合流行率.

主要成果:

包括四项包括2508名患者的研究.
综合的MDIS患病率为10% (95%CI:4%-19%).
头痛 (71.47%) 和身体疼痛 (53.08%) 是最常见的副作用. 女性性别,年龄较大,胃肠道和焦虑障碍被确定为危险因素. 患有MDIS的患者表现出更高的血压和更差的高血压控制.

结论:

在高血压患者中,MDIS的患病率很大.
在患有MDIS的患者中,高血压控制显著恶化.
需要进一步的研究,以充分解决这个研究不足的现象.

关键词:

药物不良反应药物不良反应这种高血压,高血压.多种药物不耐症综合征多种药物不耐症综合征

更多相关视频

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...